Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for ...

Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy ...

Kyorin Pharmaceutical Co. Ltd. has acquired Bayer AG’s phase II obstructive sleep apnea candidate, BAY-2925976, in a deal worth €85M (US$89.3 million) plus sales-based royalties and commercial ...

The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help ...

Bayer meanwhile recently started a fourth phase 3 trial of elinzanetant that will test the drug's ability to treat VMS associated with endocrine therapy of breast cancer. GlobalData recently ...

Cytokinetics also stands to receive up to 490 million euros from Bayer, depending on certain sales milestones. The deal covers certain uses of drug candidate aficamten in hypertrophic ...

Bayer's venerable testosterone replacement product ... Nubeqa is one of three drugs that the company is hoping will help it weather that impact on revenues, along with recently-approved diabetic ...

Regeneron (NASDAQ:REGN) announced Tuesday that Eylea HD, the high-dose version of its blockbuster eye care medication Eylea ...

FRANKFURT (Reuters) - Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an experimental heart drug, as the German group ...

Bayer is breaking into the irritable bowel syndrome (IBS) therapy market with the acquisition of HiDoc Technologies, which ...